斑秃全球、区域和国家流行病学:系统综述与建模研究
该系统综述纳入28个国家88项研究,采用贝叶斯分层线性混合模型分析斑秃患病率。全球终生患病率估计为0.10%(95%CrI 0.03-0.39),成人0.12%(95%CrI 0.02-0.52),儿童0.03%(95%CrI 0.01-0.12)。亚洲区域患病率最高,非洲最低;48%的全球疾病负担区域缺乏足够数据。
要点
- 全球斑秃终生患病率估计为0.10%,成人0.12%,儿童0.03%。
- 亚洲区域斑秃患病率最高,非洲区域最低。
- 48%的全球疾病负担区域缺乏斑秃患病或发病数据。
核心结论
- 全球斑秃终生患病率估计为0.10%(95%CrI 0.03-0.39),成人0.12%(95%CrI 0.02-0.52),儿童0.03%(95%CrI 0.01-0.12)。
- 亚洲区域斑秃患病率最高,非洲区域最低。
- 48%的全球疾病负担区域缺乏斑秃患病或发病的足够数据。
研究设计与样本
- 系统检索MEDLINE、Embase、Cochrane Library、Web of Science、SciELO和Korean Journal Database自建库至2023年10月4日的文献。
- 纳入报告斑秃患病率或发病率的研究,共纳入28个国家的88项研究。
- 采用贝叶斯分层线性混合模型分析患病率估计值,发病率数据作描述性总结。
主要发现
- 报告的斑秃发病率在19-50岁成人中趋于更高,与估计患病率趋势一致。
- 报告的总体人群患病率在男性中趋于高于女性。
- 全球终生患病率估计为0.10%(95%CrI 0.03-0.39),成人0.12%(95%CrI 0.02-0.52),儿童0.03%(95%CrI 0.01-0.12)。
- 估计患病率在亚洲区域最高,非洲区域最低。
临床怎么用
- 研究结果可为斑秃相关医疗政策决策提供参考。
- 需进一步研究中低收入国家的斑秃流行病学数据。
局限性
- 48%的全球疾病负担区域缺乏斑秃患病率或发病率的足够数据。
- 中低收入国家的流行病学信息不足,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alopecia areata (AA) is a chronic autoimmune disease that leads to a high psychiatric, economic and systemic disease burden. A comprehensive understanding of AA epidemiology is essential for evaluating healthcare source utilization; however, a systematic approach to summarizing epidemiological data on AA is lacking. OBJECTIVES: To investigate systematically the global, regional and national incidence and prevalence of AA. METHODS: A structured search was conducted using the databases MEDLINE, Embase, Cochrane Library, Web of Science, SciELO and Korean Journal Database from their date of inception to 4 October 2023. Studies that reported the prevalence or incidence of AA were included. We used a Bayesian hierarchical linear mixed model to analyse prevalence estimates. The primary outcomes of our study were the global, regional and national prevalence of physician-diagnosed AA for the overall population, for adults and for children. The incidence data were summarized descriptively. RESULTS: In total, 88 studies from 28 countries were included in the analysis. The reported incidence of AA tended to be higher in adults aged 19-50 years, and this trend was consistent with its estimated prevalence. The reported prevalence in overall populations tended to be higher in men vs. women. The estimated lifetime prevalence rate of AA was 0.10% [95% credible interval (CrI) 0.03-0.39] in the general population worldwide, 0.12% (95% CrI 0.02-0.52) in adults and 0.03% (95% CrI 0.01-0.12) in children. The estimated prevalence of AA was highest in the Asian region and lowest in the African region. CONCLUSIONS: In this study, 48% of the Global Burden of Disease regions had insufficient data on the prevalence or incidence of AA. Further studies are needed to provide epidemiological information on middle- and low-income countries. Our study may serve as a crucial reference in terms of healthcare policy decisions. Alopecia areata (AA) is a chronic autoimmune disease that can have both a psychological and physical impact on patients. An understanding of in whom, when and where the disease occurs (‘epidemiology’) is important to evaluate how healthcare resources are used in AA. There is a lack of analysis of epidemiological data in AA. This study investigated the global, regional and national incidence (the number of new cases in a specific time period) and prevalence (the rate of new cases occurring in a specific population over a specific period of time) of AA by reviewing multiple databases. Studies that reported the prevalence or incidence of AA were analysed. The primary outcomes were the global, regional and national prevalence of AA diagnosed by a doctor for the overall population, for adults only and for children only. Altogether, 88 studies from 28 countries were included in the review. The incidence of AA tended to be higher in adults aged 19–50 years, and this trend was consistent with its estimated prevalence. The estimated lifetime prevalence rate (i.e. the proportion of individuals that will be affected) of AA was 0.10% in the general population worldwide, 0.12% in adults and 0.03% in children. The estimated prevalence of AA was highest in the Asian region and lowest in the African region. Overall, we found that 48% of regions did not have enough data on the prevalence or incidence of AA. Further studies are needed to provide epidemiological data on AA, especially in middle- and low-income countries. Our results will help with healthcare policy decisions.
引用
- Jeon JJ, Jung SW, Kim YH, et al. Global, regional and national epidemiology of alopecia areata: a systematic review and modelling study. Br J Dermatol. 2024. PMID: 38332643. doi:10.1093/bjd/ljae058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。